Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ортокин-терапия – новый подход к лечению остеоартроза
Ортокин-терапия – новый подход к лечению остеоартроза
А.К.Орлецкий, А.С.Канаев, С.В.Моисеев. Ортокин-терапия – новый подход к лечению остеоартроза. Consilium Medicum. Хирургия (Прил.). 2011; 2: 8-12.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Woolf A, Pfleger B. Burden of major musculoskeletal conditions. Bull. World Health Organ 2003; 81: 646–56.
2. Jordan K, Arden N, Doherty M et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials. Ann Rheum Dis 2003; 62: 1145–55.
3. Zhang W, Moskowitz R, Nuki G et al. OARSI recommendation for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
4. Fox B, Stephens M. Treatment of knee osteoarthritis with Orthokine-derived autologus conditioned serum. Expert Rev Clin Immunol 2010; 6: 335–45.
5. Krasnokutsky S, Arrur M, Palmer G et al. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage 2008; 16: S1–S3.
6. Dinarello C. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519–50.
7. Meijer H, Reinecke J, Becker C et al. The production of antiinflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res 2003; 52 (10): 404–7.
8. Firestein G, Alvaro-Gracia J, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347–53.
9. Heilmann H, Lindenhayn K, Walther H. Synovial volume of healthy and arthrotic human knee joints. Z Orthop Ihre Grenzgeb 1996; 134: 144–8.
10. Granowitz E, Clark B, Mancilla J, Dinarello C. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266: 14147–50.
11. Frisbie D, Kawcak C, Werpy N et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68: 290–6.
12. Osterdahl J. Evaluation of autologous conditioned serum. Swed. Uni Agricultural Sci 2008; 3: 1–5.
13. Weinberger T. Clinical experience with ACS. Orthokine. IRAP in horses. Equine Sports Med Reprints 2008; 3: 1–5.
14. Caron J, Fernandes J, Tardif G et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535–44.
15. Pelletier J, Caron J, Evans C et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012–9.
16. Frisbie D, Ghivizzani S, Robbins P et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12–20.
17. Baltzer A, Drever R, Granrath M et al. Intraarticular treatment of osteoarthritis using autologous interleukine-1 receptor antagonist (IL-1Ra) conditioned serum. Dtsch Z Sportmed 2003; 54 (6): 209–11.
18. Baltzer A, Moser C, Jansen S, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009; 17 (2): 152–60.
19. Yang K, Raijmakers N, van Arkel E et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008; 16 (4): 498–505.
20. Wright-Carpenter T, Klein P, Schaferhoff P et al. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med 2004; 25 (8): 588–93.
21. Becker C, Heidersdorf S, Drewlo S et al. Efficacy of epidural perineural injection with autologus conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blinded, reference-controlled study. Spine 2007; 17: 1803–8.
2. Jordan K, Arden N, Doherty M et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials. Ann Rheum Dis 2003; 62: 1145–55.
3. Zhang W, Moskowitz R, Nuki G et al. OARSI recommendation for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
4. Fox B, Stephens M. Treatment of knee osteoarthritis with Orthokine-derived autologus conditioned serum. Expert Rev Clin Immunol 2010; 6: 335–45.
5. Krasnokutsky S, Arrur M, Palmer G et al. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage 2008; 16: S1–S3.
6. Dinarello C. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519–50.
7. Meijer H, Reinecke J, Becker C et al. The production of antiinflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res 2003; 52 (10): 404–7.
8. Firestein G, Alvaro-Gracia J, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347–53.
9. Heilmann H, Lindenhayn K, Walther H. Synovial volume of healthy and arthrotic human knee joints. Z Orthop Ihre Grenzgeb 1996; 134: 144–8.
10. Granowitz E, Clark B, Mancilla J, Dinarello C. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266: 14147–50.
11. Frisbie D, Kawcak C, Werpy N et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68: 290–6.
12. Osterdahl J. Evaluation of autologous conditioned serum. Swed. Uni Agricultural Sci 2008; 3: 1–5.
13. Weinberger T. Clinical experience with ACS. Orthokine. IRAP in horses. Equine Sports Med Reprints 2008; 3: 1–5.
14. Caron J, Fernandes J, Tardif G et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535–44.
15. Pelletier J, Caron J, Evans C et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012–9.
16. Frisbie D, Ghivizzani S, Robbins P et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12–20.
17. Baltzer A, Drever R, Granrath M et al. Intraarticular treatment of osteoarthritis using autologous interleukine-1 receptor antagonist (IL-1Ra) conditioned serum. Dtsch Z Sportmed 2003; 54 (6): 209–11.
18. Baltzer A, Moser C, Jansen S, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009; 17 (2): 152–60.
19. Yang K, Raijmakers N, van Arkel E et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008; 16 (4): 498–505.
20. Wright-Carpenter T, Klein P, Schaferhoff P et al. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med 2004; 25 (8): 588–93.
21. Becker C, Heidersdorf S, Drewlo S et al. Efficacy of epidural perineural injection with autologus conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blinded, reference-controlled study. Spine 2007; 17: 1803–8.
Авторы
А.К.Орлецкий1, А.С.Канаев2, С.В.Моисеев3
1 ФГУ ЦИТО им. Н.Н.Приорова Минздравсоцразвития РФ, Москва;
2 Кафедра травматологии, ортопедии и артрологии РУДН, Москва;
3 ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ, Москва
1 ФГУ ЦИТО им. Н.Н.Приорова Минздравсоцразвития РФ, Москва;
2 Кафедра травматологии, ортопедии и артрологии РУДН, Москва;
3 ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.